Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.51
-3.68 (-1.63%)
AAPL  274.32
-3.96 (-1.42%)
AMD  206.65
-4.13 (-1.96%)
BAC  55.45
+0.30 (0.55%)
GOOG  308.97
-1.55 (-0.50%)
META  652.30
+8.07 (1.25%)
MSFT  475.82
-2.71 (-0.57%)
NVDA  176.61
+1.59 (0.91%)
ORCL  184.47
-5.50 (-2.89%)
TSLA  480.26
+21.30 (4.64%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.